PUBLISHER: The Business Research Company | PRODUCT CODE: 1672379
PUBLISHER: The Business Research Company | PRODUCT CODE: 1672379
Genetic testing is a type of medical examination that seeks alterations in genes, proteins, or chromosomes. The results of a genetic test can identify a genetic ailment and determine a person's risk of developing a genetic disorder. This testing is utilized to confirm specific genetic disorders in children based on physical signs and symptoms.
The main types of genetic testing include predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, nutrigenomic testing, and other types. Predictive tests belong to a new and rapidly expanding class of medical tests that differ fundamentally from traditional diagnostic examinations. Various technologies are involved in genetic testing, such as cytogenetic testing, biochemical testing, and molecular testing. It is applied in several areas, including cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others, with end users including hospitals and clinics, diagnostic laboratories and centers, and others.
The genetic testing market research report is one of a series of new reports from The Business Research Company that provides genetic testing market statistics, including global market size, regional shares, competitors with a genetic testing market share, detailed genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the genetic testing industry. This genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The genetic testing market size has grown strongly in recent years. It will grow from $19.1 billion in 2024 to $20.92 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing healthcare expenditure, a rise in cancer prevalence, an increase in demand for personalized medicine, and the emergence of novel infectious diseases.
The genetic testing market size is expected to see strong growth in the next few years. It will grow to $30.45 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing government support, rising prevalence of genetic disorders, rising geriatric population, and increase in chronic disease prevalence. Major trends in the forecast period include introducing new programs such as genetic counseling and informatics programs that will assist in developing the next generation of genetic testing, technological advancement, and launching direct-to-consumer genetic tests.
The increasing prevalence of genetic disorders is expected to drive the growth of the genetic testing market in the future. Genetic disorders can manifest at birth or develop over time, and genetic testing is instrumental in diagnosing these issues and providing insights into the likelihood of developing conditions such as cancer. For example, in 2024, a report from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that genetic disorders and congenital abnormalities affect 2% to 5% of live births and account for 30% of pediatric hospital admissions, contributing to about 50% of childhood deaths in industrialized countries. Thus, the rising prevalence of genetic disorders is fueling the growth of the genetic testing market.
The escalating number of chronic diseases is expected to further drive the growth of the genetic testing market. Chronic diseases, characterized by prolonged durations often lasting a person's lifetime, necessitate informed decisions for disease prevention, management, and treatment. Genetic testing plays a crucial role in empowering individuals and healthcare providers to make such informed decisions, particularly in the context of chronic diseases. Globally, chronic diseases account for 74% of 41 million annual deaths, with cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes being major contributors, according to the World Health Organization in September 2023. Hence, the increasing prevalence of chronic diseases is a key driver of the genetic testing market.
Direct-to-consumer genetic tests represent a significant trend gaining momentum in the genetic testing market. Known as at-home DNA tests, these direct-to-consumer deoxyribonucleic acid (DNA) tests allow individuals to collect samples at home and send them off for analysis to evaluate their genetic risk for specific diseases. Home-based genetic testing analyzes individuals' DNA to identify gene variations that may increase the likelihood of developing certain medical conditions. For instance, in 2022, DNALabs, an India-based company focused on genetic testing solutions to advance personalized medicine, launched At-Home Genetic Testing Solutions. This service empowers individuals to make informed decisions with just a simple cheek swab using an at-home DNA collection kit, catering to both consumers taking charge of their health and healthcare professionals aiming to tailor optimal treatments for their patients.
The introduction of new programs is a significant trend gaining traction in the genetic testing market. Companies in this sector are emphasizing the expansion of diversity in healthcare through innovative genetic counseling and informatics initiatives that will aid in developing the next generation of genetic testing. For example, in June 2022, Illumina, Inc., a US-based company renowned for its cutting-edge technologies in genetic variation analysis, launched a research test co-developed with Merck aimed at providing deeper insights into the tumor genome. This initiative builds on Illumina's dedication to enabling comprehensive genomic profiling and bolstering research essential for precision medicine in oncology. The widely utilized TruSight Oncology 500 assay has now incorporated the evaluation of a novel genetic signature. This offering will be available globally, excluding the United States and Japan, and will assist researchers in gaining a more profound understanding of the tumor genome by identifying genetic alterations linked to homologous recombination deficiency (HRD).
In January 2022, Exact Sciences, a US-based molecular diagnostics company specializing in genetic testing products, acquired Prevention Genetics in a deal valued at $190 million. Through this acquisition, Exact Sciences intends to expand hereditary cancer testing access to more patients. Prevention Genetics, a US-based company, produces clinical DNA (genetic) tests for inherited genetic conditions.
Major companies operating in the genetic testing market include Myriad Genetics Inc, Illumina Inc, Abbott Laboratories, Eurofins Scientific, Danaher Corporation, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Qiagen NV, Thermo Fisher Scientific Inc., BioRad Laboratories Inc., BGI, Berry Genomics Co. ltd, Daan Gene Co. Ltd, Annoroad Gene Technology Co. Ltd, WuXi PharmaTech, Igenomix, Circle DNA, Centogene, Curetis, Cytena, Probably Genetic, Genome Biologics, WuXi NextCODE, Genomtec, Testgene, Evogen Lab, Phosphorus, Helix, Sequencing, 10x Genomics, Quantgene, Virica Biotech, DNALabs, Deep Genomics, SGS Mexico, Hologic Inc, 23andMe Inc, Middle East Testing Services L.L.C, Molecular Biology & Genetics Laboratory, Freiburg Medical Laboratory Middle East, IVI MIDDLE EAST FERTILITY CLINIC, Bio Certica
North America was the largest region in the genetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The genetic testing market includes revenues earned by entities by chromosomal genetic tests, molecular genetic tests (or gene tests), biochemical tests, newborn screening, and diagnostic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Genetic Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on genetic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for genetic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genetic testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.